There are different BCR-ABL1 fusion genes that are translated into proteins that are different
from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute …

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years
ago, which was a major breakthrough in stabilizing the pathology and improving the quality …

The recently approved BCR:: ABL1 tyrosine kinase inhibitor (TKI) asciminib has
demonstrated considerable activity and tolerability in newly diagnosed chronic phase …

Introduction The hallmark of chronic myeloid leukemia (CML) is the presence of
Philadelphia chromosome, its resultant fusion transcript (BCR‐ABL 1), and fusion protein …

Purpose: The aim of this study was to search the BCR/ABL 1 fusion gene in 45 chronic
myeloid leukemia (CML) Syrian patients using nested reverse transcription polymerase …

Although the majority of patients with chronic myeloid leukemia do well with treatment with
tyrosine kinase inhibitors (TKIs), some patients still have inferior outcomes. There are many …

Abstract The Philadelphia chromosome (Ph) derives from the balanced translocation
between chromosomes 9 and 22. This chromosomal translocation results in the fusion …

Objectives: A study to determine the clinical, hematological, cytogenetic, and molecular
profile in chronic myeloid leukemia (CML) patient in and around Eastern UP, India. Materials …

Objectives: There are very few published chronic myeloid leukaemia (CML) epidemiology
studies in South-East Asia and no representative from Malaysia. Methods: This is a cross …

The incidence of one or other rearrangement in chronic myeloid leukemia (CML) patients
varies in different reported series. In this study we report the frequencies of BCR-ABL1 …